Thalidomide effects in the post-transplantation setting in patients with multiple myeloma.
D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D013792:Thalidomide / Q000008:administration & dosage* / Q000633:toxicity*; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D018952:Antigens, CD34; D013792:Thalidomide